FDA
-
-
-
-
-
-
-
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
-
-
-
-
-
-
-
ADMA Biologics reports $510-511 million 2025 revenue, raises 2026 outlook
-
-
-
-
-
-
-
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
-
-
-
-
-
-
-
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
-
323,560 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

